Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3035% above fair value
$8.64−0.27 (-3.03%)
Close on Nov 20, 2026Market cap $737.11MP/E –Yield –
Monte Rosa Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Monte Rosa Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$32.08M, down 234.5% year over year. For fiscal 2025 it was -$27.50M, down 172.3% from the year before. The highest annual figure on record is $38.01M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.50M | -172.3% |
| FY2024 | Dec 31, 2024 | $38.01M | – |
| FY2023 | Dec 31, 2023 | -$62.84M | – |
| FY2022 | Dec 31, 2022 | -$105.38M | – |
| FY2021 | Dec 31, 2021 | -$69.10M | – |
| FY2020 | Dec 31, 2020 | -$26.44M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$48.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$39.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$43.78M | -134.0% |
| Q3 FY2025 | Sep 30, 2025 | $99.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$47.08M | – |
| Q4 FY2024 | Dec 31, 2024 | $128.74M | +360.7% |
| Q3 FY2024 | Sep 30, 2024 | -$21.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.55M | – |
| Q4 FY2023 | Dec 31, 2023 | $27.95M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.37M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.84M | – |
| Q1 FY2023 | Mar 31, 2023 | -$32.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.23M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.00M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.05M | – |
| Q1 FY2022 | Mar 31, 2022 | -$29.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.23M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.55M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.28M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.03M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.76M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.82M | – |
See a number that looks wrong?